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Introduction
Iloperidone is a second-generation "atypical" antipsychotic whose primary mechanism of action is within the subclass of combined D2/5HT2A antagonism, with greater affinity for the 5HT2A receptor than D2 receptor antagonism (1). Iloperidone received FDA approval in May 2009 for treatment of adults with schizophrenia, and became available in the United States for use in early 2010. At the time of this review (early 2012), iloperidone is only approved and available for prescription in the U.S. Iloperidone's benzisoxasole chemical structure and D2/5HT2A receptor affinity profile places iloperidone in the " [xyz] done" family (risperidone, ziprasidone, paliperidone) (2). Because the pronunciation of iloperidone is phonetically similar to paliperidone, it is worth emphasizing that iloperidone is not the same as paliperidone, and iloperidone is not a metabolite or derivative of any other available antipsychotic. Although iloperidone and other antipsychotics share a high affinity for both D2 and 5HT2A receptors, iloperidone has other binding affinities that give it a unique receptor binding "fingerprint. " In particular, iloperidone has a high affinity for the dopamine D3 receptor and very strong affinity for the noradrenergic A1 receptor. Iloperidone has low affinity to serotonin 5HT1A, dopamine D1 and histamine H1, and muscarinic receptors (3-7). One might predict from this binding that iloperidone will not have significant antihistaminic or anticholinergic side effects, but will have significant side effects related to its alpha-adrenergic receptor antagonist properties. Less predictable from its pharmacodynamic profile is that iloperidone has a more favorable extrapyramidal symptoms (EPS) and akathisia profile than other D2/5HT2A antagonists. Other reviews have excellent summaries of the pharmacodynamic and pharmacokinetics of iloperidone (8) . This review will focus more on how to use iloperidone in clinical practice, and its advantages and disadvantages relative to other antipsychotics available. These were 6-week, acute, head-to-head studies that were used to enter patients into a 1-year relapse prevention study. 
Iloperidone (doses) Comparator (doses)

Comment
Early study showing 4 and 8 mg subtherapeutic for acute treatment of schizophrenia. PANSS total improvement for 12 mg dose of iloperidone was 9.9 vs. 13.9 for haloperidol.
Patients who met criteria for acute response during the 6-week trial were continued on their blinded study medication (iloperidone, n=359; haloperidol, n=114). These subjects continued for up to one year in maintenance-phase treatment; primary outcome was time until (pending) relapse.
Hazard ratio of time to relapse for iloperidone vs. haloperidol subjects was 1.03 (95% CI, 0.74-1.43; p=0.86). Mean time to relapse between iloperidone and haloperidol (89.8 days vs. 101.8 days, respectively; p=0.84). During the long-term maintenance phase, the discontinuation rates were the same for iloperidone and haloperidol (36.4%).
BPRS improvement of 7.2 for risperidone vs. 6.2 lower-dose iloperidone and 7.2 higher-dose iloperidone.
The higher dose of iloperidone and risperidone >placebo. Initial analysis of the lower iloperidone dose only showed trend level differences from placebo, but FDA re-analysis, excluding schizoaffective patients, found that iloperidone 12-16 mg/day was more effective than placebo.
Similar uptitration periods for iloperidone and ziprasidone; ziprasidone > placebo; iloperidone and ziprasidone about the same efficacy.
*The regulatory objective of these three studies (3001, 3002, 3003) was to support approval for maintenance treatment of schizophrenia. However, the FDA did not accept a "noninferiority" design as adequate evidence for a maintenance indication. Therefore, at this time, iloperidone is only "labeled" for the acute treatment of schizophrenia.
†The actual study design was a "noninferiority" comparison so, strictly speaking, a statement of comparable short-term or long-term efficacy goes beyond the initial study objectives. However, the degree of symptom improvements and the K-M survival curves for time to relapse are very similar and seem comparable to most observers. ‡These two studies (3005 and 3101) were formally accepted by the FDA as the two pivotal trials being positive for efficacy of iloperidone for the treatment of schizophrenia.
Maintenance of efficacy and relapse prevention results: Subjects entering Studies 2, 3, and 4 who responded to their 6-week medication trial then entered a relapse prevention study. This was an active head-to-head comparison between haloperidol and iloperidone using a non-inferiority design. The major finding was that haloperidol and iloperidone were equally effective in relapse prevention, both statistically and by visual inspection of the K-M survival curve showing comparability of iloperidone and haloperidol in relapse prevention (see Figure 1) . Of note is that the median iloperidone maintenance dose was 13 mg/day, and many patients were on once daily dosing at 12 mg/day.
Comparative efficacy with other antipsychotics: Some of the early acute efficacy studies had active comparator antipsychotics that seemed to show relatively greater efficacy than any iloperidone dose arm. There was considerable debate as to the reason for these apparent efficacy differences. One hypothesis was that iloperidone was relatively less effective. If true, this would be the end of iloperidone as a viable treatment option for schizophrenia. The second hypothesis was that the apparent efficacy differences favoring risperidone or haloperidol were caused by the longer titration time needed for iloperidone to reach therapeutic doses than its "competitors" risperidone or haloperidol. In these 6-week trials, therapeutic doses of iloperidone were achieved in about a week whereas haloperidol and risperidone were at therapeutic by the second day. In these trials, a greater percentage of iloperidone patients dropped out within the first practice. There are a total of seven large Phase II or Phase III efficacy clinical trials. Six of the seven studies were completed in the late 1990s under the auspices of Novartis, and the last was done several years later by Vanda Pharmaceuticals. To help the reader follow this timeline, the study sponsor, date of study and location of the study sites are shown in Table 1 . This review will refer back to the studies by the study numbers shown in Table 1 .
There were four placebo-controlled acute studies, each of which also had another active comparator; haloperidol (Study 1), risperidone (Studies 5 and 6), and ziprasidone (Study 7). Three other studies (Studies 2, 3 and 4) were direct head-to-head comparisons between iloperidone and haloperidol without a placebo arm. While Studies 2, 3, and 4 were acute, their primary goal was to establish stability for a subsequent 1-year, double-blind maintenance study comparing iloperidone with haloperidol in relapse prevention. An important aspect of all of these studies is that the target dose of iloperidone was reached between 4 and 7 days, and that the initial starting dose was subtherapeutic. As will be discussed, some dose titration is necessary to minimize orthostatic hypotension and other tolerability problems related to alpha1 receptor antagonist effects.
Acute efficacy results:
The ensuing discussion summarizes the key findings of these studies. The first placebocontrolled studies (Studies 1 and 5) were primarily dose finding. Initial doses studied were 4, 8, and 12 mg/day for Study 1 (see Table 1 ), and the next study (Study 5, Table 1 ) had two flexible-dose arms, with the lowdose arm being between 4 to 8 mg/ day and a higher-dose arm between 10-16 mg/day. The lowest doses (4 and 8 mg/day) were subtherapeutic, and these studies established 10 to 12 mg as being a likely efficacious dose for the acute psychotic episode. Later studies used higher doses of iloperidone, and these studies consistently showed efficacy between 12 to 24 mg/day (Studies 6 and 7). One study (Study 6) did not seem to show a dose-response relationship between lower-and higher-dose arms, and the last study (Study 7) only used a single fixed target dose of 24 mg/day, so the information on the dose-response relationship between 12 and 24 mg is not well understood. The efficacy of iloperidone for the treatment of schizophrenia, therefore, seems comparable to other first-line antipsychotics, both for short-term acute treatment and for relapse prevention. While a slow uptitration schedule might indeed be a clinical issue in practice, this was altogether a very different type of problem than iloperidone being intrinsically less effective.
Target Dose and Recommended DoseTitration Schedule
The recommended target dose for iloperidone for the acute treatment of schizophrenia is between 12 mg (e.g., 6 mg twice a day) and 24 mg (12 mg bid). The half-life of iloperidone is 18 hours, suggesting that it can be dosed on a once-a-day schedule. Iloperidone is labeled for twice-a-day dosing not because of its half-life, but to minimize orthostatic hypotension during the uptitration phase.
For acutely ill, relapsing patients, the goal of the dosetitration schedule is to reach therapeutic doses of iloperidone as quickly as reasonably possible. The low end of the target dose is 12 mg given as 6 mg twice a day and has a 4-day uptitration schedule; the high end is 24 mg (as 12 mg twice a day), and this is a 7-day schedule (see Table 2 ). As will be discussed later, slower uptitration strategies can be used when minimizing alpha-related side effects is a priority.
Dose Adjustments Based on Drug-Drug Interactions
Iloperidone is metabolized by the liver cytochrome P450 (CYP) system. The specific enzyme pathways are CYP3A4 and CYP2D6. Therefore, the dosing of iloperidone should be adjusted for patients taking other medications known to inhibit CYP3A4 or CYP2D6 systems and, therefore, inhibit metabolism (e.g., increase plasma level) of iloperidone. Among patients with schizophrenia, the most common drug-drug interactions occur when patients receive adjunctive antidepressants that inhibit CYP2D6 metabolism, with fluoxetine, paroxetine, and venlafaxine being common exam- comparable efficacy between iloperidone and haloperidol in the three direct head-to-head comparison studies (see Figure 2) ; the apparent efficacy advantages favoring haloperidol or risperidone go away after taking into account dosetitration differences that handicapped iloperidone. These analyses include using better statistical methods or by excluding the early dropouts in these trials (see Figure 3) ; and, 1.
2.
the final pivotal study (Study 7) was designed to address the dose-titration question and used a comparable uptitration schedule between iloperidone and ziprasidone and, in fact, showed very similar efficacy between the two antipsychotics (see Figure 4 ).
3.
ples. Likewise, co-treatment with a potent CYP3A4 inhibitor such as ketoconazole (or drinking grapefruit juice, another CYP3A4 inhibitor) will also inhibit iloperidone metabolism and increase plasma concentrations of iloperidone and its active metabolites by about 50%. Iloperidone dosing should be reduced by 50% for patients who are taking a strong CY-P2D6 AND/OR CYP3A4 inhibitor. Because cigarette smoking induces the CYP1A2 system-which is not a primary CYP enzyme for iloperidone-iloperidone dosing is not affected by smoking status. Iloperidone can be dosed with or without food (2, 9, 10).
Dose-Response Issues
There is a robust dose-response relationship at the lower end of the therapeutic dose range. Doses lower than 12 mg/ day are less likely to be effective. One study showed an efficacy signal at 8 mg/day (Study 5); at least one other fixeddose study found that the 8 mg/day dose was not effective (Study 1). In contrast, the 12 mg/day has been consistently efficacious. Unless there are special dose adjustments needed because of drug-drug interactions or other special considerations, the low end of therapeutic target dose is 12 mg/day. There remains some uncertainty about the dose-response characteristics at the higher end of the recommended dosage range (e.g., between 16 and 24 mg total daily dose). There are no efficacy studies above 24 mg/day. Many patients appear to respond to a therapeutic target dose in the lower end of the dose range (e.g., 12-16 mg/day total daily dose) may be most appropriate, especially when starting iloperidone in outpatient settings. There is a suggestion from one pharmacokinetic/pharmacodynamic modeling study that assessed response by plasma level that showed a robust plasma level/ response effect at plasma levels ≤10 ug/ml without any further efficacy at higher plasma levels (11).
In summary, the current understanding of dose response is:
Side Effects, Safety and Tolerability
Because antipsychotics are a basic part of the psychopharmacology of schizophrenia, the tolerability relative to other available antipsychotics is very important (see Table 3 for a summary). Other reviews of iloperidone have focused on the integrated safety database that was submitted to the FDA and can be found in the package insert, as well as other reviews. This review will shift the focus to compare the tolerability profile of iloperidone to other antipsychotics whose tolerability profiles are already known in clinical practice. This will be easiest to do for the specific antipsychotics that have been used in parallel design studies with iloperidone: haloa fairly robust dose-response relationship at the lower end of the recommended dose range, with doses <10 mg/day likely to be subtherapeutic for many patients; while the current evidence on dose-response relationship between 12 and 24 mg/day is still inconclusive, the absence of a clear dose-response relationship between the approved 12 and 24 mg dose range suggests that iloperidone does not have a steep dose-response curve within the approved dose range (12); and, in the long-term flexible dose-maintenance study, the modal dose of iloperidone was 12 mg/day even though an only relatively small percentage of patients was given the maximal allowable dose of 16 mg/day, suggesting that the lower end of the dose range may be therapeutic for many individuals stabilized on iloperidone.
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peridol, risperidone, and ziprasidone. Therefore, these three antipsychotics will serve as the primary point of contrast.
Akathisia
Iloperidone has an excellent akathisia profile. In clinical trials, there is no signal of akathisia over and above that seen in placebo. More recent analysis of pooled acute trials shows that the trajectory of akathisia over acute treatment is virtually the same as the placebo group. The only other first-line antipsychotic with an equally favorable akathisia profile is quetiapine, so iloperidone and quetiapine now share a "best in class" designation for low akathisia risk.
Antipsychotic-Induced Parkinsonism
Although antipsychotic-induced parkinsonism is to be expected with any D2 antagonist, it is difficult to find a parkinsonism signal for iloperidone at any dose within the 
Contrast with Other Antipsychotics
Akathisia from iloperidone < risperidone < ziprasidone or haloperidol.
EPS rates from iloperidone < ziprasidone < risperidone < haloperidol.
Iloperidone ≈ ziprasidone.
While sedation is common in clinical trials, the rates of somnolence do not appear markedly different than haloperidol or risperidone in 6-week clinical trials.
Prolactin elevation from risperidone >> iloperidone, haloperidol > iloperidone, ziprasidone ≈ iloperidone.
Weight gain from iloperidone > haloperidol and ziprasidone, iloperidone ≈ risperidone. See weight gain text for comparisons.
Is associated with greater QTc prolongation than some other antipsychotics. Safety of QTc extensively studied, including higher doses and with metabolic inhibitors, without any observed safety problems.
Antipsychotic-induced orthostatic hypotension is from peripheral alpha1 receptor antagonism (13). Orthostatic hypotension from iloperidone >> haloperidol and > risperidone.
Comment
Probably similar to quetiapine: very little signal for akathisia in that there is no difference between iloperidone and placebo in akathisia rates, and no dose relationship with akathisia.
Probably similar to quetiapine in that no dose/ EPS relationship and unlikely to need adjunctive anticholinergics.
No observed increase in fasting cholesterol or triglycerides associated with iloperidone.
Consistent with lack of strong affinity to H1 histamine receptor, sedation from iloperidone seems comparable to other antipsychotics associated with relatively little sedation.
Some prolactin elevation in clinical trials but unlikely to be clinically significant for most patients.
Based on maintenance studies, it appears that most of the weight gain occurs in the first 6 weeks and tends to stabilize from there. Also, there seems to be a clinically significant dose effect with higher doses (20-24 mg) associated with more weight gain than lower doses).
Some QTc elevation without any reports of clinically significant problems (e.g., arrhythmia). Labeling in package insert similar to ziprasidone.
Qualitatively similar to risperidone or quetiapine but greater magnitude than those agents. Like risperidone, may be associated with retrograde ejaculation in younger men (common) (15). May be associated with priapism (rare) (16).
safety database. Furthermore, the EPS profile compares very favorably to the other available antipsychotics included in the iloperidone clinical trials program. Furthermore, this favorable EPS profile occurs with relatively little in the way of concurrent anticholinergic treatment.
Dyslipidemia
The best comparative data on lipid changes come from the most recent clinical trial of iloperidone because this has carefully measured fasting lab values for ziprasidone, as well as iloperidone and placebo. Iloperidone and ziprasidone were basically equivalent with no adverse impact on fasting triglycerides: change from baseline at 4 weeks associated with iloperidone was +0.8 mg/dL; ziprasidone was +4.6 mg/dL; and, placebo was a +19.5 mg/dL increase. Likewise, fasting cholesterol changes were negligible, with iloperidone +8.1 mg/dL; ziprasidone +4.1 mg/dL; and, placebo -0.5 mg/dL.
Prolactin-Related Effects
Like most antipsychotics, there is a transient increase in plasma prolactin associated with acute onset of treatment. The mean increase at the highest dose (24 mg/day) was only 2.6 ng/mL (not clinically significant). In a pooled analysis of iloperidone versus other active comparators, iloperidone and ziprasidone were not associated with clinically relevant prolactin elevation (-2 ng/mL and +2 ng/mL, respectively), whereas haloperidol and risperidone had significant elevation (23 ng/mL and 34 ng/mL, respectively) (13). Therefore, iloperidone treatment is unlikely to cause clinically relevant problems associated with prolactin elevation (e.g., amenorrhea or galactorrhea in premenopausal women).
Weight Gain
The information from the safety database shows that short-term weight gain (4 to 6 weeks) is 2.0 kg compared to -0.1 kg for placebo-treated patients. There seems to be a plateau because long-term weight gain is only slightly higher at 2.1 kg. These overall estimates are limited in that they do not inform clinicians on weight gain relative to other options. When compared with ziprasidone, the "best in class" (Study 7), iloperidone patients gained 2.8 kg while ziprasidone patients gained 1.1 kg. The best comparative data for long-term maintenance treatment come from the iloperidone versus haloperidol relapse prevention studies (see Table 1 , Studies 2, 3, and 4). In the first six weeks of acute treatment, iloperidone was associated with a 2.6 kg weight gain whereas haloperidol weight gain was 0.6 kg. Over the next year of maintenance therapy, patients on iloperidone gained on average an additional 1.2 kg compared to 1.7 kg for haloperidol-treated patients. Total weight gain over the entire period was 4.8 kg for iloperidone versus 3.0 with haloperidol. In other words, iloperidone was associated with an average of 1.8 kg greater weight gain over the course of a year relative to haloperidol. Another unusual aspect of the weight profile for iloperidone is that it seems to depend on the target dose, with 18% of patients receiving higher doses (20-24 mg/day) meeting categorical cutoff criteria for >7% gain in body weight compared to only 12% of patients receiving lower doses of iloperidone (10-16 mg/day).
Sedation
Short-term sedation associated with iloperidone is dose related, with overall adverse events of "somnolence" being reported in 5.7% of iloperidone patients at low-target doses (10-16 mg/day) and 8.0% at the high end of the dose range (20-24 mg/day). Haloperidol (15 mg/day) had a 6.8% and risperidone (4-8 mg/day) a 5.9% somnolence rate. There is no marked difference between iloperidone at lower target doses with the others, and all antipsychotics had greater likelihood of somnolence than the placebo rate of 2.7%. In the long-term maintenance study, sedation was reported in 2% of the iloperidone subjects and 5% of haloperidol subjects. Overall, the pattern of sedation reports would suggest that iloperidone will have a sedation profile more like haloperidol and risperidone than the more sedating agents such as quetiapine or olanzapine.
QTc Prolongation
Iloperidone has some propensity to prolong the QTc interval, which for some drugs has been associated with a theoretical risk of arrhythmia (Torsade de Pointes [TdP] ). The safety of iloperidone has been extensively studied in a safety study where maximal doses were used and metabolic inhibitors added. The mean QTc elevation at maximal recommended dose of 12 mg twice a day was 9.6 msec, and when iloperidone was given as a single dose of 24 mg the QTc elevation was 15.4 msec. Of course, the real issue is arrhythmia risk, which has not been reported for iloperidone. From a practical perspective, iloperidone seems to be very similar to ziprasidone in that it has a higher QTc elevation than some other antipsychotics, and is not associated with any increased relative risk of arrhythmia or sudden death (17). Like ziprasidone and paliperidone, the package insert for iloperidone suggests that clinicians consider the relatively greater QTc prolongation associated with these antipsychotics when considering iloperidone. Having said that, no deaths or serious arrhythmias have ever been associated with iloperidone exposure, including overdose experience.
Side Effects Related to Peripheral Alpha1 Antagonist
Iloperidone has strong alpha1 adrenergic antagonist properties. While noradrenergic A1 antagonism is hardly unique and is associated with most antipsychotics, iloperidone has one of the highest relative affinities for this receptor. Like clozapine, quetiapine, and risperidone, acute alpha1 adrenergic antagonism will predictably cause transient cardiovascular symptoms such as tachycardia or orthostatic hypotension (14) . Therefore, all of these antipsychotics have dose-titration schedules to minimize the potential effects of alpha blockade on blood pressure. Within this framework, then, most clinicians who prescribe any of these agents will already be familiar with management of alpha side effects. However, the relative binding affinity of iloperidone to the A1 receptor to the D2 dopamine receptor is higher than any other antipsychotic except clozapine. For example, in a pooled analysis across 6-week acute inpatient trials, dizziness as an adverse event ranged from 10.3% at lower end of therapeutic doses of iloperidone (10-12 mg/total daily dose) to 23.2% at the high end of the therapeutic dose range (20 to 24 mg/day). In contrast, dizziness as an adverse event occurred in 5.1% and 7.2% of subjects receiving haloperidol (15 mg/day) and risperidone (4-8 mg/day total daily dose), respectively (18). This suggests that clinicians should expect approximately that patients will experience these types of adverse events at roughly double that of comparable therapeutic doses of risperidone. Therefore, clinicians should anticipate that the peripheral manifestations of alpha1 antagonism will be more common than risperidone. Therefore, relative to risperidone, iloperidone has a slower uptitration period, and will also have relatively higher rates of dizziness and orthostatic hypotension than risperidone.
Using Iloperidone in Clinical Practice
General Indications
In the last decade, the FDA has narrowed the diagnostic categories when approving antipsychotics. Iloperidone is approved for the treatment of patients with schizophrenia. Although the FDA considers schizoaffective disorder as a separate disease category from schizophrenia, most clinicians are comfortable prescribing any antipsychotic approved for schizophrenia for patients with schizoaffective disorder. Iloperidone has not been evaluated in bipolar disorder and is not indicated for bipolar disorder. Iloperidone has not been studied in children. There is a commitment on Novartis' part to the FDA to conduct clinical trials in children, but until this is done, it should probably not be used without compelling reason in children because of the lack of clinical data and the QTc labeling precaution. Like other atypical antipsychotics, there is a "black box" warning reminding clinicians of the mortality signal for use in elderly patients for behavioral manifestations of dementia. In addition to this class warning, the propensity for iloperidone to cause orthostatic hypotension would be an additional reason to consider other antipsychotics in the frail elderly.
Relative Advantages of Iloperidone
Clinicians have more choices between antipsychotic medications than ever before, and are interested in knowing the clinical circumstances in which iloperidone may have some specific advantages over other possible choices. Some of the clinical circumstances where iloperidone might be potentially helpful include:
Exploiting differential efficacy for patients with persistent symptoms who have not been exposed to iloperidone: The rationale is to use the unique pharmacodynamic profile of iloperidone to offer a different antipsychotic to partial antipsychotic responders who have not yet been exposed to iloperidone. Given that relatively few patients have been exposed to iloperidone, iloperidone may be a good "efficacy switch" candidate to maximize overall exposure to antipsychotics that have not been tried for any given partial responder. Notice that this relative advantage of iloperidone is based on the relative sequencing of approval and availability rather than any signal of greater efficacy over other options. The same rationale can be used for other recently approved antipsychotics (e.g., asenapine or lurasidone) that have also not been widely prescribed.
EPS and akathisia remain very significant problems even in the era of atypical antipsychotics: It appears that among first-line antipsychotics, iloperidone and quetiapine share a "best in class" property of having a very low propensity to cause either antipsychotic-induced parkinsonism or akathisia. This makes iloperidone a very appealing consideration for any patient who is very sensitive to, or concerned about, antipsychotic-induced parkinsonism or akathisia. Although the newer antipsychotics are generally less associated with EPS or akathisia, many patients will continue to have these problems, albeit in an attenuated manner. Like quetiapine, anticholinergic agents are rarely prescribed for patients taking iloperidone and, like quetiapine, there seems to be no dose-EPS or dose-akathisia signal across therapeutic dose range.
Selecting iloperidone for its overall favorable tolerability profile to reduce the overall side effect burden: As shown in Table 4 , iloperidone has an excellent tolerability profile across almost all common tolerability problems. In addition to the lack of EPS and akathisia signal, it is not very sedating, is not likely to cause clinically significant prolactin elevation, and is not associated with elevated lipids or cholesterol. While iloperidone is associated with modest weight gain, the weight gain usually falls within medically and psychologically acceptable parameters. Finally, although orthostatic hypotension and other side effects related to noradrenergic A1 antagonism are more problematic with iloperidone than most other antipsychotics, these problems tend to abate with time and, therefore, do not add to long-term burden once the initial dose-titration period is over.
Concerns and Contraindications for Iloperidone
Concern over QTc prolongation labeling: Iloperidone is contraindicated when the patient is already taking another medication with QTc elevation that meets "black box" labeling criteria. Among psychotropic medications, this includes thioridazine, pimozide, and droperidol. There is significant variation among clinicians on "comfort level, " and it is beyond the scope of this review to go into great detail except to remind the reader that there is no clinical signal of actual cardiac safety risk (17).
When risk of orthostatic hypotension is medically significant: Orthostatic hypotension and other alpha concerns-patients who are already showing signs of orthostatic hypotension will be very sensitive to having their blood Acute efficacy equivalent to other first-line antipsychotics.
Relapse prevention comparable to haloperidol.
Relative lack of EPS or akathisia may allow therapeutic dosing for patients whose doses are otherwise limited by these effects.
Target dose range established and flexible.
Tolerability related
Excellent EPS and akathisia profile makes it an excellent choice for patients with known sensitivities.
Low use of anticholinergics because of low EPS will reduce anticholinergic burden.
Overall tolerability profile is favorable, such that it may reduce overall side effect burden associated with long-term antipsychotic therapy.
Not associated with elevations in triglycerides or cholesterol.
Patients will accommodate to cardiovascular problems associated with peripheral alpha1 receptor antagonism so these are unlikely to cause persistent tolerability problems.
Other clinical issues
Pharmacokinetics and clinical experience support daily dosing after alpha1 receptor antagonism problems abate.
Relatively good subjective tolerability may help long-term adherence in some patients.
Flexible dosing options.
No need to take with food; no interactions with cigarette smoking.
Many dosage strengths.
Potential Disadvantages
Not shown to be more effective than other first-line antipsychotics.
Delays in reaching therapeutic dosing in acute psychotic episode may delay start of therapeutic efficacy.
No data on efficacy in bipolar disorder or other indications.
Dose response between 12 and 24 mg range not clearly established.
There may be medical risks associated with orthostatic hypotension in vulnerable patients, and may also cause transient distress during initiation.
QTc labeling may discourage using iloperidone as first-line agent.
Associated with modest weight gain.
Some A1 adverse events may persist (e.g., retrograde ejaculation).
Labeled only for twice-a-day use.
Complex initiation regimen may be challenging, especially in outpatients with difficulty following directions.
Higher costs associated with a "branded" antipsychotic.
Certain drug-drug interactions are clinically significant (CYP3A4 and CYP2D6), and many psychiatric medications are metabolized by CYP2D6. No short-acting or long-acting injectable formulations.
pressure "bottom out. " Elderly and frail patients where fainting or falling could be catastrophic would be a relative contraindication to iloperidone relative to other antipsychotics that have lower affinity for this receptor.
When there is an urgent need to start at therapeutic doses of antipsychotic medication: Because of the delay in reaching therapeutic dose, iloperidone is at a relative disadvantage when there is an urgent need to start at full therapeutic dose. An example might be an outpatient who is relapsing but not hospitalized, and who poses a safety concern because of the acute psychotic symptoms.
When the patient needs a long-acting antipsychotic: At this time, only a short-acting oral formulation of iloperidone is available. If a long-acting injectable therapy is needed, then another antipsychotic with a depot formulation would be preferable.
When clozapine is needed:
There is no evidence that iloperidone has any specific clozapine-like properties for treatment-resistant schizophrenia, and should not be considered a substitute for clozapine when it is indicated When there are access or cost barriers: Iloperidone is relatively new and may not be available in all formularies. It also is expensive, at least relative to other atypical antipsychotics going generic over the next few years, so many patients will have prescription coverage that is "fail first" with one or more antipsychotics such as risperidone. Clinicians should consider access before initiating iloperidone to avoid having to change medications for reasons unrelated to clinical reasons.
Switching Outpatients To Iloperidone
Recall that the recommended dose-titration schedule for iloperidone was developed for acutely ill, relapsing patients, where getting to therapeutic quickly was the priority. However, for stable but symptomatic outpatients already on another antipsychotic, other pharmacologic priorities may be more important. Under those conditions, clinicians may want to minimize the severity of orthostatic hypotension, dizziness and tachycardia associated with rapid uptitration to therapeutic doses. The delay in achieving the desired target dose is not as much of a clinical concern as long as the previous antipsychotic is continued at therapeutic doses. Risk factors for clinically significant cardiovascular effects when using any alpha1 receptor antagonist include: Table 5 is a checklist for an elective crossover to iloperidone when the immediate goal is to minimize early adverse effects from alpha-adrenergic receptor antagonism. Clinicians choosing a slower cross-titration approach should be aware that this is "off label" and has not been formally studied in the iloperidone clinical trial program.
Speculations and Future Directions
Speculations A large part of this review has dealt with managing peripheral alpha1 receptor antagonism. Of course, iloperidone crosses the blood-brain barrier and will have central effects as well. The potential therapeutic role of strong central A1 antagonism is a matter of speculation, but some authors have reviewed alpha and hypothesize it has a central role in antipsychotic efficacy (22) . Recently, there is a growing appreciation of the role of central alpha1 antagonism in ameliorating symptoms of posttraumatic stress disorder (PTSD). Whether iloperidone may have specific therapeutic benefits for schizophrenia patients, who also have symptoms of PTSD, is intriguing and is of obvious theoretical and practical importance.
The relative lack of EPS or akathisia is puzzling. Looking at the strength of the D2 receptor antagonism associated with iloperidone, one would expect more in the way of EPS or akathisia liability, even when considering the mitigating role of 5HT2A antagonism. Perhaps the alpha receptor plays a role here. Again, it is intriguing that the two other 1. already being at risk for orthostatic hypotension prior to starting medication; 2. the rapidity of the dose increases; 3. the eventual target doses; and, 4. the effectiveness of patient education on minimizing problems during the iloperidone cross-taper. Review whether the patient is taking another medication that has pharmacokinetic drug-drug interaction that would be likely to increase the plasma level of iloperidone (and, therefore, increase initial side effects). Most common examples in psychiatric patients will be antidepressants that are metabolized through the CYP2D6 system.
Review whether there are any pre-existing risk factors for orthostatic hypotension unrelated to iloperidone (e.g., diabetes mellitus, antihypertensives, etc.) that might already be causing orthostatic hypotension.
Review history of having received other medications with alpha1 receptor antagonism (e.g., risperidone, quetiapine, clozapine) and assess how patient handled initiation and dose increases on these medications.
Educate the patient about minimizing any new symptoms of orthostatic hypotension (and other A1 side effects).
Assuming you want to minimize the likelihood of alpha antagonist, consider a slower uptitration of iloperidone than used in the package insert.
If possible, use the dose titration pack but at a slower uptitration schedule than suggested. Alert the patient that the dosing change schedule will differ from the instructions, and review carefully the revised uptitration schedule.
Remember that iloperidone is likely to be subtherapeutic until 12 mg/day total daily dose is reached, and that the prior antipsychotic should be continued at therapeutic doses during the iloperidone uptitration period.
Remind the patient (and family) that most of the peripheral alpha side effects are transient and will abate shortly after achieving target dose. Therefore, any discomfort or inconvenience is likely to be transient.
Once at target dose of iloperidone, then taper and discontinue the prior antipsychotic medication.
Other aspects of switching strategies are consistent with principles of switching between antipsychotic medications and have been reviewed elsewhere (19-21).
antipsychotics associated with the lowest EPS and akathisia liability-clozapine and quetiapine-share with iloperidone a strong propensity for alpha1 receptor antagonism. The availability of another antipsychotic with a very low EPS and akathisia liability may also reinvigorate interest in the deleterious effects of even "mild" forms of EPS and akathisia. While there is no doubt that many patients benefit enormously from the relatively lower EPS and akathisia liabilities associated with the newer medications, "less EPS" is not the same as "no EPS. " It may be easier to recognize the existence of more subtle behavioral EPS toxicities when there are more ways to successfully address these conditions.
Future Directions
Personalized predictors of efficacy: One of the Phase III trials evaluated potential genetic markers of response and found specific combinations of genetic markers could be used as specific predictors of response to iloperidone, but not ziprasidone. This initial step into personalized medicine, if replicated in future studies, would have dramatic impact on the medication evaluation process. However, to date, the initial findings have apparently not been replicated, and others seem to find the markers as general not specific predictors (23). Until there is a consistent and replicated genetic marker of response, clinicians need to use other factors in medication selection.
Other indications: At this time (January 2012), the author is not aware of any active clinical trials evaluating the efficacy of iloperidone in other psychiatric disorders.
Long-acting formulations:
There is an active research effort into developing a long-acting injectable formulation of iloperidone. Given the excellent tolerability and efficacy profile of the oral version, a long-acting version with comparable effectiveness would be a major advance.
